ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
P/S ratio for ImmunoGen, Inc. (IMGN)
P/S ratio as of 2022: 11.56
According to ImmunoGen, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.56. At the end of 2021 the company had a P/S ratio of 17.30.
P/S ratio history for ImmunoGen, Inc. from 1988 to 2022
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2022 | 11.56 |
| 2021 | 17.30 |
| 2020 | 8.59 |
| 2019 | 9.21 |
| 2018 | 12.48 |
| 2017 | 5.45 |
| 2016 | 3.65 |
| 2015 | 4.46 |
| 2014 | 14.46 |
| 2013 | 16.91 |
| 2012 | 40.67 |
| 2011 | 78.61 |
| 2010 | 43.52 |
| 2009 | 39.12 |
| 2008 | 15.73 |
| 2007 | 3.27 |
| 2006 | 6.07 |
| 2005 | 4.02 |
| 2004 | 6.62 |
| 2003 | 9.51 |
| 2002 | 23.46 |
| 2001 | 15.90 |
| 2000 | 163.75 |
| 1999 | 31.84 |
| 1998 | 15.94 |
| 1997 | 70.61 |
| 1996 | 69.64 |
| 1995 | 106.25 |
| 1994 | 97.55 |
| 1993 | 53.55 |
| 1992 | 40.41 |
| 1991 | 43.93 |
| 1990 | 25.78 |
| 1989 | 71.06 |
| 1988 | 18.72 |